Metagenomi (MGX) Revenue & Revenue Breakdown
Metagenomi Revenue Highlights
Latest Revenue (Y)
$44.76M
Latest Revenue (Q)
$8.66M
Metagenomi Revenue by Period
Metagenomi Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $44.76M | 160.21% |
| 2022-12-31 | $17.20M | 6978.19% |
| 2021-12-31 | $243.00K | - |
Metagenomi generated $44.76M in revenue during NA 2023, up 160.21% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Metagenomi Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2025-09-30 | $8.66M | 1.72% |
| 2025-06-30 | $8.51M | 106.28% |
| 2025-03-31 | $4.13M | -57.07% |
| 2024-12-31 | $9.61M | -16.50% |
| 2024-09-30 | $11.51M | -42.45% |
| 2024-06-30 | $20.01M | 79.30% |
| 2024-03-31 | $11.16M | -10.00% |
| 2023-12-31 | $12.40M | 0.29% |
| 2023-09-30 | $12.36M | 9.05% |
| 2023-06-30 | $11.34M | 30.96% |
| 2023-03-31 | $8.66M | 54.73% |
| 2022-12-31 | $5.59M | 13.88% |
| 2022-09-30 | $4.91M | 46.83% |
| 2022-06-30 | $3.35M | - |
| 2022-03-31 | $3.35M | - |
Metagenomi generated $8.66M in revenue during Q3 2025, up 1.72% compared to the previous quarter, and up 43.28% compared to the same period a year ago.
Metagenomi Revenue Breakdown
Metagenomi Revenue Breakdown by Product
Quarterly Revenue by Product
| Product/Service | Sep 25 | Jun 25 | Mar 25 |
|---|---|---|---|
| Operating Segments | $8.66M | $8.51M | $4.13M |
Latest
Metagenomi's latest quarterly revenue breakdown by segment (product or service), as of Sep 25: Operating Segments (100.00%).
Metagenomi Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| DTIL | Precision BioSciences | $68.70M | $13.00K |
| STRO | Sutro Biopharma | $62.04M | $9.69M |
| MGX | Metagenomi | $44.76M | $8.66M |
| ARTV | Artiva Biotherapeutics | $33.49M | - |
| CNTB | Connect Biopharma | $26.03M | $48.00K |
| ADVM | Adverum Bio | $1.00M | - |
| ATYR | aTyr Pharma | $353.00K | $190.00K |
| IFRX | InflaRx | $61.80K | $36.25K |
| ALXO | ALX Oncology | - | - |
| QNCX | Quince Therapeutics | - | - |
| KLRS | Kalaris Therapeutics | - | - |